Mirum Pharmaceuticals financials
$87.54−0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $176.2M | $159.9M | $148.9M | $133.0M | $127.8M | $111.6M | $99.4M | $90.4M | $77.9M | $69.2M | $69.6M | $47.7M |
| Gross profit | $145.9M | $131.1M | $120.7M | $107.5M | $104.4M | $88.6M | $76.6M | $69.6M | $57.6M | $51.4M | $44.5M | $37.5M |
| Gross margin | 82.8% | 82.0% | 81.0% | 80.8% | 81.7% | 79.4% | 77.1% | 77.0% | 74.0% | 74.2% | 64.0% | 78.6% |
| Operating income | -$42.5M | -$789.5M | -$4.6M | $2.6M | -$5.0M | -$15.2M | -$24.2M | -$12.7M | -$24.2M | -$26.5M | -$32.6M | -$25.1M |
| Net income | -$67.2M | -$790.2M | -$5.7M | $2.9M | -$5.9M | -$14.7M | -$23.8M | -$14.2M | -$24.6M | -$25.3M | -$35.7M | -$23.6M |
| Net margin | −38.1% | −494.2% | −3.8% | 2.2% | −4.6% | −13.2% | −23.9% | −15.8% | −31.6% | −36.5% | −51.3% | −49.4% |
| Diluted EPS | $-1.06 | $-13.43 | $-0.13 | $0.05 | $-0.12 | $-0.30 | $-0.49 | $-0.30 | $-0.52 | $-0.54 | $-0.76 | $-0.57 |
| EBITDA | -$35.6M | -$782.6M | $1.5M | $8.7M | $1.1M | -$9.1M | -$18.2M | -$6.6M | -$18.4M | -$20.8M | -$32.6M | -$22.5M |
| Operating cash flow | -$44.3M | -$228.8M | $6.1M | $39.7M | $12.0M | -$2.0M | -$5.1M | $4.0M | -$3.8M | $15.2M | -$16.6M | -$18.2M |
| Free cash flow | -$44.3M | -$229.4M | $5.5M | $39.5M | $11.9M | -$2.0M | -$5.1M | $3.8M | -$4.6M | $15.2M | -$16.6M | -$18.2M |
| Diluted shares | 63.4M | 58.9M | 45.2M | 57.0M | 49.7M | 48.9M | 48.1M | 47.8M | 47.2M | 46.9M | 46.7M | 41.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $330.7M | $324.9M | $296.7M | $282.0M | $228.1M | $211.8M |
| Short-term investments | $107.6M | $61.4M | $86.6M | $93.5M | $76.4M | $65.9M |
| Total debt | $750.1M | $310.3M | $309.8M | $309.4M | $308.9M | $308.5M |
| Total assets | $1.04B | $890.9M | $842.8M | $785.1M | $725.8M | $690.2M |
| Total liabilities | $1.06B | $648.4M | $528.1M | $493.1M | $470.7M | $457.0M |
| Shareholders' equity | -$10.4M | $242.5M | $314.7M | $292.0M | $255.2M | $233.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology